Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) Pharmaceutical Industries Ltd. (TEVA) has announced the creation of a Global Specialty Medicines (GSM) group. Dr. Rob Koremans will serve as president and CEO Global Specialty Medicines. He will continue to serve on Teva’s Executive Committee and report to Teva president and CEO Dr. Jeremy Levin.
"The newly created Global Specialty Medicines group significantly reinforces Teva's commitment to our patients, customers, and healthcare providers, as it combines the strong local presence we have established in high-quality and accessible generics with our global scale and capabilities in specialty medicines," said Dr. Levin. "The GSM group will work seamlessly with our regional generics teams. They will complement each other and establish a single, differentiated Teva presence in the market. The creation of this group is a stepping stone in our strategy to optimize our commercialization, and it paves the path forward to make Teva the most indispensable medicines company for the world."
Dr. Koremans said, “Teva has an impressive portfolio of specialty medicines, and this move will further emphasize and strengthen our leadership and innovation in this field. Teva’s unique capabilities in specialty pharmaceuticals are now concentrated in the new GSM group, so we can deliver more effectively on our commitment to our patients and other stakeholders.” Teva also announced that Dipankar Bhattacharjee, formerly Senior Vice President Western Europe, has been promoted to the position of president and CEO of Generics Europe, reporting to Dr. Levin. Mr. Bhattacharjee will also join the Teva Executive Team.
Larry Downey, formerly Executive Vice President of Teva US Brands, has been appointed president, North America Specialty Medicines, reporting to Dr. Koremans.
Published by Globes [online], Israel business news - www.globes-online.com - on April 24, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013